IMTX - Immatics N.V. Debt to Book Capitalization Ratio

Immatics N.V. (IMTX) is developing T-cell oncology therapies, positioning itself as a future pricing power leader in the absence of comparable alternatives. The strategy is based on deep R&D and alliances with pharmaceutical behemoths without pursuing mergers. The infrastructure relies on German laboratories and its own manufacturing plant in the US. This chart reflects the current share price on GURU.Markets at 0.04, demonstrating the market valuation of this innovative business.

IMTX Immatics N.V.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/28/2026

Summary analytical data breakdowns for Immatics NV (IMTX)

- price and consensus price forecast:

Stock Price Immatics N.V.|IMTX - Consensus Target

- market capitalization data:

Market Value Immatics Biotechnologies|IMTX - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Immatics|IMTX - Company Book Value|Market Value to Book Value Ratio immatics.com|IMTX - Company Assets

- debt and liquidity data:

Total Debt to Capital Immatics N.V.|IMTX - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Immatics Corp|IMTX - Company Cumulative Debt|Debt to Book Value Immatics Biotechnologies

Analysis of all company metrics:IMTX, Immatics N.V.

Finished products of Immatics Biotechnologies

This indicator determines the degree of capital structure dependence on borrowed funds by comparing total debt obligations to the book value of equity. Analyzing the debt-to-capitalization ratio allows for an assessment of the financial stability of Immatics N.V. (IMTX), whose high profitability is supported by flawless cold chain logistics during the transportation of complex immuno-oncology drugs.

Competitors of Immatics N.V.